Effectiveness Of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD)

This interventional trial (n=30) will assess the efficacy and safety of Psychedelic Therapy for Post Traumatic Stress Disorder (PTSD) using MDMA.

Participants will receive MDMA medicines orally in capsule form once in the morning on specific medicine days, alongside psychotherapy sessions. The treatment regimen involves three preparatory sessions, a dosing session lasting approximately 6-7 hours, and three integration sessions, all conducted over several weeks. The therapy sessions will be led by HREC approved psychologists/psychotherapists and a psychiatrist.

The study aims to evaluate changes in clinician-rated PTSD symptoms, trauma, adverse events, personality disorder symptoms, disability, connection, relationships, mystical experiences, alcohol use, drug use, suicidal ideation, depression, eating attitudes, disordered eating, and eating disorder symptomology from baseline to 2 weeks post-treatment.

The trial is recruiting participants in New South Wales, Australia, with a target of 30 participants. It is funded by self-funding and is led by Prof Dr Ranil Gunewardene. For further information, individuals can contact Dr Ranil Gunewardene at Mindlife Clinic Northern Beaches Hospital.

Topic PTSD
Compound MDMA
Country Australia
Visit trial
Status Recruiting
Results Published No
Start date 04 December 2023
End date 05 January 2029
Phase Phase IV
Design Open
Type Interventional
Generation First
Participants 30
Sex All
Age 18- 65
Therapy Yes

Trial Details

We intend to measure the effectiveness of psychedelic assisted medicines (methylene dioxy methamphetamine - MDMA) when combined with talking therapy; for the treatment of Post Traumatic Stress Disorder in real world patient groups We will test how effective MDMA is for PTSD and treat patients who have had limited benefits with existing treatments for these hard to treat conditions.

NCT Number ACTRN12624000041550

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.